Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes ...

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...